Theranexus SA (FR:ALTHX) has released an update.
Theranexus, in collaboration with the Beyond Batten Disease Foundation, reports positive 18-month results from its phase 1/2 study of Batten-1, indicating a significant decrease in neurofilament light chains, a key biomarker of neuronal death in juvenile Batten disease. The consistent findings highlight the therapeutic potential of Batten-1, with plans to proceed to pivotal phase 3 trials in Europe and the US. Additionally, a compassionate access program has been implemented for ongoing patient treatment.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
